dc.contributor.author | Wright, LB | |
dc.contributor.author | Schoemaker, MJ | |
dc.contributor.author | Jones, ME | |
dc.contributor.author | Ashworth, A | |
dc.contributor.author | Swerdlow, AJ | |
dc.date.accessioned | 2018-03-27T10:21:04Z | |
dc.date.accessioned | 2018-04-04T09:57:10Z | |
dc.date.issued | 2018-08-15 | |
dc.identifier.citation | International journal of cancer, 2018, 143 (4), pp. 782 - 792 | |
dc.identifier.issn | 0020-7136 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1627 | |
dc.identifier.eissn | 1097-0215 | |
dc.identifier.doi | 10.1002/ijc.31364 | |
dc.description.abstract | Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and hyperemesis with an increased risk, but the evidence remains unclear. We used data from the Generations Study, a large prospective study of women in the United Kingdom, to estimate relative risks of breast cancer in relation to a history of preeclampsia and hyperemesis using Cox regression adjusting for known breast cancer risk factors. During 7.5 years average follow-up of 82,053 parous women, 1,969 were diagnosed with invasive or in situ breast cancer. Women who had experienced preeclampsia during pregnancy had a significantly decreased risk of premenopausal breast cancer (hazard ratio (HR) =0.67, 95% confidence interval (CI): 0.49-0.90) and of HER2-enriched tumours (HR = 0.33, 95% CI: 0.12-0.91), but there was no association with overall (HR = 0.90, 95% CI: 0.80-1.02) or postmenopausal (HR = 0.97, 95% CI: 0.85-1.12) breast cancer risk. Risk reductions among premenopausal women were strongest within 20 years since the last pregnancy with preeclampsia. Hyperemesis was associated with a significantly increased risk of HER2-enriched tumours (HR = 1.76, 95% CI: 1.07-2.87), but not with other intrinsic subtypes or breast cancer risk overall. These results provide evidence that preeclampsia is associated with a decreased risk of premenopausal and HER2-enriched breast cancer and that hyperemesis, although not associated with breast cancer risk overall, may be associated with raised risk of HER2-enriched tumours. | |
dc.format | Print-Electronic | |
dc.format.extent | 782 - 792 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.relation.replaces | https://repository.icr.ac.uk/handle/internal/1610 | |
dc.relation.replaces | internal/1610 | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Neoplasm Invasiveness | |
dc.subject | Pre-Eclampsia | |
dc.subject | Hyperemesis Gravidarum | |
dc.subject | Receptor, erbB-2 | |
dc.subject | Proportional Hazards Models | |
dc.subject | Risk Factors | |
dc.subject | Follow-Up Studies | |
dc.subject | Prospective Studies | |
dc.subject | Pregnancy | |
dc.subject | Postmenopause | |
dc.subject | Premenopause | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | United Kingdom | |
dc.subject | Breast Carcinoma In Situ | |
dc.title | Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-03-01 | |
rioxxterms.versionofrecord | 10.1002/ijc.31364 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | International journal of cancer | |
pubs.issue | 4 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology | |
pubs.publication-status | Published | |
pubs.volume | 143 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Aetiological Epidemiology | |
dc.contributor.icrauthor | Wright, Lauren | |
dc.contributor.icrauthor | Schoemaker, Minouk | |
dc.contributor.icrauthor | Jones, Michael | |
dc.contributor.icrauthor | Swerdlow, Anthony | |